Overview

A Study of LY3499446 in Participants With Advanced Solid Tumors With KRAS G12C Mutation

Status:
Terminated
Trial end date:
2020-10-30
Target enrollment:
Participant gender:
Summary
The reason for this study is to see if the study drug LY3499446 is safe and effective in participants with solid tumors with KRAS G12C mutation.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Cetuximab
Docetaxel
Erlotinib Hydrochloride